SML2737
AER-271
≥98% (HPLC)
别名:
2-(3,5-bis(Trifluoromethyl)phenylcarbamoyl)-4-chlorophenyl dihydrogen phosphate, AER-270 phosphate, AER-270 precursor, AER-270 prodrug, IMD-0354 phosphate, IMD-0354 precursor, IMD-0354 prodrug, N-[3,5-bis(Trifluoromethyl)phenyl]-5-chloro-2-(phosphonooxy)benzamide
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
FC(F)(F)c1cc(cc(c1)C(F)(F)F)NC(=O)c2c(ccc(c2)Cl)O[P](=O)(O)O
InChI key
WSHXPHFIHYXZKC-UHFFFAOYSA-N
Biochem/physiol Actions
AER-271 is a phosphonate precursor (prodrug) form of the selective aquaporin 4 (AQP4) inhibitor IMD-0354 (AER-270; hu/m/r IC50 = 420/390/210 nM using respective CHO AQP4 transfectants) with >5000-fold enhanced solubility. AER-271 is rapidly converted to AER-270 in vivo (plasma AER-270 Cmax = 500 ng/mL or 1.75 μM, 20 min post 10 mg AER-271/kg i.p.; C57BL/6 mice) and exhibits therapeutic efficacy in rodent models of brain damage by cardiac arrest or ischemic stroke (5-10 mg/kg ip. & 0.08 mg/h sc. in mice; 1-10 mg/kg iv. in rats).
Phosphonate precursor (prodrug) of the selective aquaporin 4 (AQP4) inhibitor IMD-0354 (AER-270) with in vivo efficacy in rodent models of brain damage.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable